the invention in its broad aspects includes derivatives of amino acids and related compounds having formula i above . within this broad group , because of their properties , certain subgroups are preferred over others . compounds in the group represented by formula i which are derived from or include the structure of the amino acids alanine leucine , threonine , phenylalanine , lysine , arginine , glutamine , histidine , methionine , tyrosine , valine , asparagine or tryptophan are broadly preferred . especially preferred modifications are compounds of formula i wherein n is 2 , r 1 is guanidino - lower alkylene ( particularly guanidinopropyl ), amino - lower alkylene ( particularly amino - c 3 - c 4 - lower alkylene ) or phenyl - lower alkylene ( particularly phenylmethyl ); r 2 is hydrogen or lower alkyl ( particularly hydrogen or methyl ); r 3 is lower alkyl ( particularly methyl ); and r 4 is hydroxy or hydroxyamino . the lower alkyl groups represented by any of the variables include straight and branched chain hydrocarbon radicals from methyl to heptyl , for example , methyl , ethyl , propyl , isopropyl , butyl , isobutyl , t - butyl , pentyl , isopentyl and the like . the lower alkylene groups are of the same kind having 1 to 7 carbons . similarly the lower alkoxy groups are of the same kind with a link to oxygen , for example , methoxy , ethoxy , propoxy , isopropoxy , butoxy , isobutoxy , t - butoxy and the like . the c 1 - c 4 members , especially c 1 and c 2 members , of all types are preferred . phenylmethyl is the preferred phenyl - lower alkylene group and methoxy the preferred lower alkoxy group . the products of formula i and the preferred subgroups can be produced by various methods of synthesis . according to a preferred method , an acid of the formula ## str3 ## wherein r 1 and r 2 are defined as above is coupled with a monoester of a succinic or glutaric acid of the formula ## str4 ## wherein r 3 has the meaning defined above , by one of the known procedures in which the acid iii is activated , prior to reaction with the acid ii , involving formation of a mixed anhydride , symmetrical anhydride , acid chloride , active ester , woodward reagent k , n , n &# 39 ;- carbonylbisimidazole , eedq ( n - ethoxycarbonyl - 2 - ethoxy - 1 , 2 - dihydroquinoline ) or the like . [ for a review of these methods , see methoden der organischen chemie ( houben - weyl ) vol . xv , parts 1 and 2 ( 1974 )]. the product of this reaction is a compound of the formula ## str5 ## which is saponified , e . g ., with a base like sodium hydroxide , in conventional manner to obtain the free diacid ## str6 ## conversely the free acid can be esterified by conventional procedures . as a modification of the above procedure , an ester of the acid of formula ii , e . g ., a lower alkyl ester or an aralkyl ester , can be used in the reaction with the monoester of formula iii to obtain a compound of the formula ## str7 ## wherein r and r 5 are ester groups , e . g ., lower alkoxy or aralkyloxy . other coupling reagents such as dicyclohexylcarbodiimide can be used in addition to those referred to above . hydroxylaminolysis of the acid iv or treatment of the acid iv with hydroxylamine yields the hydroxamic acid ## str8 ## the succinic acid monoesters of formula iii ( i . e ., n is 1 ) are prepared by alcoholysis of the corresponding substituted succinic anhydride . it is preferred to obtain products wherein the ester function is β to the alkyl side chain . in order to obtain the required regiospecificity in the alcoholysis reaction , an alkylidene succinic anhydride is preferably used to obtain the starting monoester , e . g ., an anhydride of the formula ## str9 ## wherein r &# 39 ; is hydrogen , lower alkyl or phenyl and this is treated with an alcohol r &# 39 ;&# 39 ;&# 39 ; oh to obtain the product ## str10 ## then reduction with hydrogen yields the monoester ## str11 ## similarly , in the case of the glutaric acids , ( i . e ., n is 2 ), alkylidene derivatives are used . when such alkylidene derivatives are not readily available , the substituted glutaric anhydride is subjected to alcoholysis followed by careful purification of the monoester by fractional crystallization of the dicyclohexylammonium salt . products of formula i have at least one asymmetric carbon and two if r 1 is other than hydrogen . these carbon atoms are indicated by an asterisk in formula i . the compounds accordingly exist in diastereoisomeric forms or in racemic mixtures thereof . all of these are within the scope of the invention . the above described synthesis can utilize the racemate or one of the enantiomers as starting material . when the racemic starting material is used in the synthetic procedure , the stereoisomers obtained in the product can be separated by conventional chromatographic or fractional crystallization methods . in general , the l - isomer with respect to the carbon of the amino acid constitutes the preferred isomeric form . the compounds of this invention form basic salts with various inorganic and organic bases which are also within the scope of the invention . such salts include ammonium salts , alkali metal salts like sodium and potassium salts ( which are preferred ), alkaline earth metal salts like the calcium and magnesium salts , salts with organic bases , e . g ., dicyclohexylamine salt , benzathine , n - methyl - d - glucamine , hydrabamine salts , salts with amino acids like arginine , lysine and the like . the non - toxic , physiologically acceptable salts are preferred , although other salts are also useful , e . g ., in isolating or purifying the product , as illustrated in the examples in the case of the dicyclohexylamine salt . the salts are formed in conventional manner by reacting the free acid form of the product with one or more equivalents of the appropriate base providing the desired cation in a solvent or medium in which the salt is insoluble , or in water and removing the water by freeze drying . by neutralizing the salt with an insoluble acid like a cation exchange resin in the hydrogen form [ e . g ., polystyrene sulfonic acid resin -- dowex 50 ( mikes , laboratory handbook of chromatographic methods ( van nostrand , 1961 ) page 256 ] or with an aqueous acid and extraction with an organic solvent , e . g ., ethyl acetate , dichloromethane or the like , the free acid form can be obtained , and , if desired , another salt formed . additional experimental details are found in the examples which are preferred embodiments and also serve as models for the preparation of other members of the group . the compounds of this invention inhibit the conversion of the decapeptide angiotensin i to angiotensin ii and therefore are useful in reducing or relieving angiotensin related hypertension . the action of the enzyme renin on angiotensinogen , a pseudoglobulin in blood plasma , produces angiotensin i . angiotensin i is converted by angiotensin converting enzyme ( ace ) to angiotensin ii . the latter is an active pressor substance present which has been implicated as the causative agent in various forms of hypertension in various mammalia n species , e . g ., rats , dogs , etc . the compounds of this invention intervene in the renin → angiotensin i → angiotensin ii sequence by inhibiting angiotensin converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin ii . thus by the administration of a composition containing one or a combination of compounds of formula i or physiologically acceptable salt thereof , angiotensin dependent hypertension in the species of mammal suffering therefrom is alleviated . a single dose , or preferably two to four divided daily doses , provided on a basis of about 1 to 1000 mg . per kilogram per day , preferably about 10 to 100 mg . per kilogram per day is appropriate to reduce blood pressure as indicated in the animal model experiments described by s . l . engel , t . r . schaeffer , m . h . waugh and b . rubin , proc . soc . exp . biol . med . 143 ( 1973 ). the substance is preferably administered orally , but parenteral routes such as subcutaneously , intramuscularly , intravenously or intraperitoneally can also be employed . the compounds of this invention can be utilized to achieve the reduction of blood pressure by formulating in compositions such as tablets , capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration . about 10 to 500 mg . of a compound or mixture of compounds of formula i or physiologically acceptable salt is compounded with a physiologically acceptable vehicle , carrier , excipient , binder , preservative , stabilizer , flavor , etc ., in a unit dosage form as called for by accepted pharmaceutical practice . the amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained . illustrative of the adjuvants which may be incorporated in tablets , capsules and the like are the following : a binder such as gum tragacanth , acacia , corn starch or gelatin ; an excipient such as dicalcium phosphate ; a disintegrating agent such as corn starch , potato starch , alginic acid and the like ; a lubricant such as magnesium stearate ; a sweetening agent such as sucrose , lactose or saccharin ; a flavoring agent such as peppermint , oil of wintergreen or cherry . when the dosage unit form is a capsule , it may contain in addition to materials of the above type , a liquid carrier such as a fatty oil . various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit . for instance , tablets may be coated with shellac , sugar or both . a syrup or elixir may contain the active compound , sucrose as a sweetening agent , methyl and propyl parabens as preservatives , a dye and a flavoring such as cherry or orange flavor . sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection , a naturally occurring vegetable oil like sesame oil , coconut oil , peanut oil , cottonseed oil , etc ., or a synthetic fatty vehicle like ethyl oleate or the like . buffers , preservatives , antioxidants and the like can be incorporated as required . the following examples are illustrative of the invention and constitute especially preferred embodiments . all temperatures are in degrees celsius . l - alanine benzyl ester ( 44 . 7 g .) and hydroxybenzotriazole ( 34 g .) are dissolved in dioxane ( 750 ml .) and the solution is chilled with stirring in an ice - water bath . dicyclohexylcarbodiimide ( 51 . 5 g .) and 3 - methoxycarbonyl - 2 - methylpropanoic acid ( 36 g . ), prepared by hydrogenation of 3 - methoxycarbonyl - 2 - methylene propanoic acid , are added in that order and the mixture is stirred at room temperature for 18 hours . the precipitate is filtered off , and the filtrate is concentrated to dryness in vacuo . the residue is dissolved in ethyl acetate and washed neutral . the ethyl acetate is dried over magnesium sulfate and concentrated to dryness in vacuo to yield n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine benzyl ester . n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine benzyl ester ( 50 g .) is dissolved in 95 % ethanol , 10 % palladium on charcoal ( 5 g .) is added and the mixture is hydrogenated at normal pressure for 16 hours . the catalyst is filtered off and the filtrate is concentrated to dryness in vacuo to yield n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine . n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine ( 9 . 7 g .) is dissolved in a mixture of methanol ( 137 ml .) and n sodium hydroxide ( 137 ml .) and the solution is stirred at room temperature for five hours . the free diacid is isolated by chromatography on a dowex 50 ion exchange resin . n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine ( 2 . 17 g .) is dissolved in absolute ethanol ( 8 ml .). an ethanolic solution of hydroxylamine [ prepared from hydroxylamine hydrochloride ( 0 . 7 g .) and sodium ethylate ] is added followed by a solution of sodium ( 0 . 23 g .) in absolute ethanol ( 8 ml .). after two hours , the reaction mixture is added to vigorously stirred ether ( 500 ml .). the precipitate is filtered and dried to obtain n -( 3 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - alanine sodium salt . the free acid is prepared by treatment with an ion exchange resin ( doxex 50 in the hydrogen form ). by substituting l - leucine benzyl ester for the l - alanine benzyl ester in the procedure of example 1 , and then treating the product by the procedures of examples 2 and 3 , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - leucine benzyl ester , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - leucine , and n -( 3 - carboxy - 2 - methylpropanoyl )- l - leucine are obtained . by substituting n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - leucine for n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 3 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - leucine is obtained . by substituting o - benzyl - l - threonine benzyl ester for the l - alanine benzyl ester in the procedure of example 1 , and then treating the product by the procedures of examples 2 and 3 , n -( 3 - metoxycarbonyl - 2 - methylpropanoyl )- o - benzyl - l - threonine benzyl ester , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - threonine and n -( 3 - carboxy - 2 - methylpropanoyl )- l - threonine are obtained . by substituting n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - threonine for n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 3 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - threonine is obtained . by substituting l - phenylalanine benzyl ester for the l - alanine benzyl ester in the procedure of example 1 , and then treating the product by the procedures of examples 2 and 3 , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - phenylalanine benzyl ester , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - phenylalanine and n -( 3 - carboxy - 2 - methylpropanoyl )- l - phenylalanine are obtained . by substituting n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - phenylalanine for n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 3 - hydroxy - carbamoyl - 2 - methylpropanoyl )- l - phenylalanine is obtained . by substituting n . sup . ε - benzyloxycarbonyl - l - lysine benzyl ester for the l - alanine benzyl ester in the procedure of example 1 , and then treating the product by the procedure of examples 2 and 3 , n . sup . α -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- n . sup . ε - benzyloxycarbonyl - l - lysine benzyl ester , n . sup . α -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - lysine , and n . sup . α -( 3 - carboxy - 2 - methylpropanoyl )- l - lysine are obtained . by substituting n . sup . α -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - lysine for n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n . sup . α -( 3 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - lysine is obtained . by substituting nitro - l - arginine benzyl ester for the l - alanine in the procedure of example 1 , and then treating the product by the procedures of examples 2 and 3 , n . sup . α -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- nitro - l - arginine benzyl ester , n . sup . α -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - arginine and n . sup . α -( 3 - carboxy - 2 - methylpropanoyl - l - arginine are obtained . by substituting n . sup . α -( 3 - methoxycarbonyl - 2 - methylpropanoyl - l - arginine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n . sup . α -( 3 - hydroxy - carbamoyl - 2 - methylpropanoyl )- l - arginine is obtained . by substituting l - glutamine benzyl ester for the alanine benzyl ester in the procedure of example 1 , and then treating the product by the procedure of examples 2 and 3 , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - glutamine benzyl ester , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - glutamine and n -( 3 - carboxy - 2 - methylpropanoyl )- l - glutamine are obtained . by substituting n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - glutamine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl - l - alanine in the procedure of example 4 , n -( 3 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - glutamine is obtained . by substituting l - histidine p - nitrobenzyl ester for the l - alanine benzyl ester in the procedure of example 1 and then treating the product by the procedures of examples 2 and 3 , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - histidine p - nitrobenzyl ester , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - histidine , and n -( 3 - carboxy - 2 - methylpropanoyl )- l - histidine are obtained . by substituting n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - histidine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 3 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - histidine is obtained . by substituting l - methionine methyl ester for the l - alanine benzyl ester in the procedure of example 1 , and then treating the product by the procedure of example 3 , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - methionine methyl ester , and n -( 3 - carboxy - 2 - methylpropanoyl )- l - methionine are obtained . by substituting l - tyrosine benzyl ester for the l - alanine benzyl ester in the procedure of example 1 , and then treating the product by the procedure of examples 2 and 3 , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - tyrosine benzyl ester , n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - tyrosine and n -( 3 - carboxy - 2 - methylpropanoyl )- l - tyrosine are obtained . 3 - methoxycarbonyl - 2 - d - benzylpropanoic acid ( 4 . 4 g .) is dissolved in dioxane ( 40 ml .). n - hydroxysuccinimide ( 2 . 3 g .) and dicyclohexylcarbodiimide ( 4 . 12 g .) are added and the mixture is stirred at room temperature overnight . the precipitate is filtered and the filtrate is concentrated to dryness and the residue is crystallized from ethyl acetate to yield 3 . 67 g . of 3 - methoxycarbonyl - 2 - d - benzylpropanoic acid n - hydroxysuccinimide ester , m . p . 111 °- 113 °. this ester ( 4 . 8 g .) dissolved in pyridine ( 24 ml .) is added to a suspension of l - phenylalanine ( 4 . 95 g .) in a solution of sodium bicarbonate ( 3 . 75 g .) in water ( 24 ml .). after eight hours the reaction mixture is diluted with water and extracted with ethyl acetate . the aqueous phase is acidified and extracted with ethyl acetate . this ethyl acetate is concentrated to dryness and the product is crystallized from ether to yield 2 . 1 g . of n -( 3 - methoxycarbonyl - 2 - d - benzylpropanoyl )- l - phenylalanine , m . p . 100 °- 104 °. n -( 3 - methoxycarbonyl - 2 - d - benzylpropanoyl )- l - phenylalanine ( 1 . 18 g .) is dissolved in dichloromethane ( 32 ml .) and the solution is chilled to - 10 °. molar boron tribromide solution in dichloromethane ( 16 ml .) is added and the reaction is allowed to proceed 1 hour at - 10 ° and 18 hours at room temperature . water and ethyl acetate are added and the organic phase is separated and concentrated to dryness . the residue is crystallized from ethyl acetate to yield 0 . 5 g . of n -( 3 - carboxy - 2 - d - benzylpropanoyl )- l - phenylalanine m . p . 144 °- 145 °. 2 - methylglutaric acid ( 14 . 6 g .) and acetyl chloride ( 26 ml .) are heated in the steam bath for one hour . the mixture is concentrated to dryness in vacuo and the residue is evaporated twice from toluene . the residue is dissolved in methanol ( 4 . 7 ml .) and heated on the steam bath for one hour and concentrated to dryness . the residue is dissolved in a mixture of ether ( 17 ml . ), dicyclohexylamine ( 16 . 7 ml .) and hexane ( 83 ml .). the crystalline salt is filtered off and the filtrate is concentrated to one third volume and chilled . the crystals are filtered and dried to yield 11 . 3 g . of 4 - methoxycarbonyl - 2 - methyl butanoic acid dicyclohexylamine salt , m . p . 97 °- 99 °. the salt is converted to the free acid by distribution between ethyl acetate and aqueous acid . l - alanine benzyl ester ( 3 . 58 g .) and hydroxybenzotriazole ( 2 . 7 g .) are dissolved in dichloromethane . the solution is chilled in the ice bath and dicyclohexylcarbodiimide ( 4 . 12 g .) is added . after stirring 15 minutes in the ice bath and 18 hours at room temperature the precipitate is filtered off and the filtrate is concentrated to dryness . the residue is dissolved in ethyl acetate and washed neutral . the organic phase is dried over magnesium sulfate and concentrated to dryness to yield n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - alanine benzyl ester . n -( 4 - methoxycarbonyl )- 2 - methylbutanoyl - l - alanine benzyl ester ( 4 g .) is dissolved in 95 % ethanol ( 40 ml .) 10 % palladium on charcoal ( 0 . 5 g .) is added and the mixture is hydrogenated at normal pressure for 16 hours . the catalyst is filtered off and the filtrate is concentrated to dryness in vacuo to give n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - alanine . by substituting n -( 3 - methoxycarbonyl - 2 - methylbutanoyl )- l - alanine for the n -( 4 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 4 - hydroxycarbamoyl - 2 - methylbutanoyl )- l - alanine is obtained . n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - alanine ( 9 . 0 g .) is dissolved in a mixture of methanol ( 130 ml .) and n - sodium hydroxide ( 13 ml .) and the solution is stirred at room temperature for five hours . the free diacid is isolated by chromatography on a dowex 50 ion exchange column . by substituting l - valine benzyl ester for the l - alanine benzyl ester in the procedure of example 23 and then treating the product by the procedure of examples 24 and 26 , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - valine benzyl ester , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - valine and n -( 4 - carboxy - 2 - methylbutanoyl )- l - valine are obtained . by substituting n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - valine for n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 4 - hydroxycarbamoyl - 2 - methylbutanoyl )- l - valine is obtained . by substituting o - benzyl - l - threonine benzyl ester for l - alanine benzyl ester in the procedure of example 23 , and then treating the product by the procedures of examples 24 and 26 , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - benzyl - l - threonine benzyl ester , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - threonine , and n -( 4 - carboxy - 2 - methylbutanoyl )- l - threonine are obtained . by substituting n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - threonine for the ( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 4 - hydroxycarbamoyl - 2 - methylbutanoyl )- l - threonine is obtained . by substituting l - asparagine p - nitrobenzyl ester for the l - alanine benzyl ester in the procedure of example 23 , and then treating the product by the procedures of examples 24 and 26 , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - asparagine p - nitrobenzyl ester , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - asparagine and n -( 4 - carboxy - 2 - methylbutanoyl )- l - asparagine are obtained . by substituting n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - asparagine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 4 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - asparagine is obtained . by substituting n . sup . ε - benzyloxycarbonyl - l - lysine benzyl ester for the l - alanine benzyl ester in the procedure of example 23 and then treating the product by the procedures of examples 24 and 26 , n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- n . sup . ε - benzyloxycarbonyl - l - lysine benzyl ester , n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - lysine and n . sup . α -( 4 - carboxy )- 2 - methylbutanoyl )- l - lysine are obtained . by substituting n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - lysine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n . sup . α -( 4 - hydroxycarbamoyl - 2 - methylbutanoyl )- l - lysine is obtained . by substituting nitro - l - arginine benzyl ester for the l - alanine benzyl ester in the procedure of example 23 , and then treating the product by the procedures of examples 24 and 26 , n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- nitro - l - arginine benzyl ester , n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - arginine , and n . sup . α -( 4 - carboxy - 2 - methylbutanoyl )- l - arginine are obtained . by substituting n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - arginine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n . sup . α -( 4 - hydroxy - carbamoyl - 2 - methylbutanoyl )- l - arginine is obtained . by substituting l - histidine p - nitrobenzyl ester for the l - alanine benzyl ester in the procedure of example 23 , and then treating the product by the procedures of examples 24 and 26 , n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - histidine p - nitrobenzyl ester , n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - histidine , and n . sup . α -( 4 - carboxy - 2 - methylbutanoyl )- l - histidine are obtained . by substituting n . sup . α -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - histidine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n . sup . α -( 4 - hydroxycarbamoyl - 2 - methylbutanoyl )- l - histidine is obtained . by substituting l - methionine methyl ester for the l - alanine benzyl ester in the procedure of example 23 , and then treating the product by the procedure of example 26 , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - methionine methyl ester and n -( 4 - carboxy - 2 - methylbutanoyl )- l - methionine are obtained . by substituting l - tryptophane benzyl ester for the l - alanine benzyl ester in the procedure of example 23 , and then treating the product by the procedures of examples 24 and 26 , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - tryptophane benzyl ester , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - tryptophane and n -( 4 - carboxy - 2 - methylbutanoyl )- l - tryptophane are obtained . by substituting l - tyrosine benzyl ester for the l - alanine benzyl ester in the procedure of example 23 , and then treating the product by the procedure of examples 24 and 26 , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - tyrosine benzyl ester , n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - tyrosine , and n -( 4 - carboxy - 2 - methylbutanoyl )- l - tyrosine are obtained . by substituting n -( 4 - methoxycarbonyl - 2 - methylbutanoyl )- l - tyrosine for the n -( 3 - methoxycarbonyl - 2 - methylpropanoyl )- l - alanine in the procedure of example 4 , n -( 4 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - tyrosine is obtained . the racemic forms of the final products in each of the foregoing examples are produced by utilizing the dl - form of the starting amino acid instead of the l - form . similarly the d - form of the final products in each of the foregoing examples is produced by utilizing the d - form of the starting amino acid instead of the l - form . 1000 tablets each containing 100 mg . of n . sup . α -( 3 - carboxy - 2 - methylpropanoyl )- l - arginine are produced from the following ingredients : ______________________________________n . sup . α -( 3 - carboxy - 2 - methylpropanoyl )- l - arginine 100 g . corn starch 50 g . gelatin 7 . 5 g . avicel ( microcrystalline cellulose ) 25 g . magnesium stearate 2 . 5 g . ______________________________________ the n . sup . α -( 3 - carboxy - 2 - methylpropanoyl )- l - arginine and corn starch are admixed with an aqueous solution of the gelatin . the mixture is dried and ground to a fine powder . the avicel and then the magnesium stearate are admixed with the granulation . this is then compressed in a tablet press to form 1000 tablets each containing 100 g . of active ingredient . two piece # 1 gelatin capsules each containing 250 mg . of n . sup . α -( 3 - hydroxycarbamoyl - 2 - methylpropanoyl )- l - lysine are filled with a mixture of the following ingredients : ______________________________________n . sup . α -( 3 - hydroxycarbamoyl - 2 - methyl - propanoyl )- l - lysine 250 mg . magnesium stearate 7 mg . usp lactose 193 mg . ______________________________________
new carboxyalkylacylamino acids which have the general formula ## str1 ## are useful as angiotensin converting enzyme inhibitors .